Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Cancer Med. 2024 Jun;13(11):e7237. doi: 10.1002/cam4.7237.
To examine the risk of second primary cancer in patients with incident renal cell carcinoma (RCC).
We identified all patients diagnosed with incident RCC during 1995-2019, using population-based Danish medical registries. Patients were followed from the date of RCC diagnosis until any second primary cancer diagnosis, death, emigration, or December 31, 2019, whichever came first. We computed the absolute risk, standardized incidence ratio (SIR), and excess absolute risk of second primary cancer, with 95% confidence intervals (CIs), among patients with RCC compared to the general population.
The absolute 1- and 20-year risks of any second primary cancer were 2.8% and 17.8%, respectively. Within 1 year after RCC diagnosis, we detected 20 excess cancer cases per 1000 person-years (PY) (SIR, 2.3; 95% CI: 2.1-2.6). Moreover, we detected an additional four excess cancer cases per 1000 PY during 1 to <5 years of follow-up (SIR, 1.3; 95% CI: 1.2-1.4), and 6 per 1000 PY beyond 5 years of follow-up (SIR, 1.4; 95% CI: 1.3-1.5). The sustained elevated cancer risk beyond 1 year of follow-up was mainly attributed to excess risk of lung and bladder cancer. The risk of second primary cancer was higher in 2006-2019 than in 1995-2005, but only during the first year of follow-up.
Patients with incident RCC have a sustained 40% elevated long-term risk of second primary cancer, compared with the general population. This increased risk is mainly attributed to lung and bladder cancer.
研究初发肾细胞癌(RCC)患者发生第二原发癌的风险。
我们利用基于人群的丹麦医学登记处,确定了 1995 年至 2019 年期间所有诊断为初发 RCC 的患者。患者自 RCC 诊断之日起至发生第二原发癌、死亡、移民或 2019 年 12 月 31 日(以先发生者为准)止进行随访。我们计算了 RCC 患者与普通人群相比第二原发癌的绝对风险、标准化发病比(SIR)和超额绝对风险,并计算了 95%置信区间(CI)。
任何第二原发癌的 1 年和 20 年绝对风险分别为 2.8%和 17.8%。在 RCC 诊断后 1 年内,我们检测到每 1000 人年(PY)有 20 例癌症超额病例(SIR,2.3;95%CI:2.1-2.6)。此外,在 1 至<5 年的随访期间,我们还检测到每 1000 PY 额外的 4 例癌症超额病例(SIR,1.3;95%CI:1.2-1.4),在随访 5 年以上时,每 1000 PY 检测到 6 例癌症超额病例(SIR,1.4;95%CI:1.3-1.5)。1 年随访后持续升高的癌症风险主要归因于肺癌和膀胱癌的超额风险。2006-2019 年与 1995-2005 年相比,第二原发癌的风险更高,但仅在随访的第一年。
与普通人群相比,初发 RCC 患者发生第二原发癌的长期风险持续升高 40%。这种风险增加主要归因于肺癌和膀胱癌。